With its family of brands and relentless global expansion, Isodiol posts May 2018 revenues of $3,345,389 CDN.
VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F)(the “Company” or “Isodiol”), a global CBD innovator specializing in hemp based health and wellness products, the development of pharmaceutical CBD delivery methods and the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products (FPPs), announces unaudited May 2018 consolidated revenue numbers of $3,316,646 CDN.
Marcos Agramont, CEO of Isodiol, stated, “May was a historic month for revenues. These numbers legitimize what we have accomplished over the last several months, particularly with the acquisitions of KURE Corp and BSPG Laboratories, Ltd. Shareholders can expect audited financials for the period of April 1, 2017 – March 31, 2018 to be available on July 30th, 2018.”
The company has officially opened its new Corporate Headquarters at 2710 – 200 Granville St., Vancouver, BC V6C 1S4. The new location will allow the company to continue to grow its management team and to focus on Canadian sales and expansion as cannabis laws continue to positively change within Canada.
Two of the company’s flagship medical products, Isoderm and Purodiol, were recently featured at the International League Against Epilepsy in Sao Paola, Brazil. The congress was hosted by neurology experts from around the world. “As the company continues to expand its international footprint, it is crucial that we stay at the forefront of these conferences and educate the medical community about our approved deliveries of CBD and the recent approval of our API for use in finished pharmaceutical products, said Agramont.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nano-technology for the highest quality consumable and topical skin care products. Most recently, the company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.